Ask a room of clinicians how patients find newer depression treatments and you will hear a confident story. Patients read about it online, see an ad or a video, and come in asking for it by name. Our data suggests it is mostly wrong.
Our survey of 443 Midwest adults, Missourians among them, included a write-in question on the words they would search in a bad stretch. For primary care physicians and referrers in St. Charles County, here are six assumptions about patient searching, checked against what people told us. Figures cover the full ten-state sample, in its validated final form.
Assumption: patients arrive having researched specific treatments
Some do. Most, by their own account, have not. The 319 people who answered our open search question overwhelmingly wrote plain descriptions of what they felt or wanted, such as "ptsd help" or "help with depression." No phrase we are reporting names a treatment.
Assumption: a patient who wants a newer treatment will ask for it by name
They cannot ask for something they have never heard of. Put Spravato, the esketamine nasal spray with an FDA approval in treatment-resistant depression, in front of respondents and nearly three quarters had never met the name. One in five knew the name but not the product. Fewer than one in ten could describe it.
The practical consequence for a St. Charles practice is that the patient most likely to benefit from a conversation about options for treatment-resistant depression is also the patient least likely to start it. Waiting for a request means waiting for something that rarely comes.
Assumption: online marketing moves patients more than we do
This one is especially worth retiring. The recommendation most likely to get respondents to try a newer depression treatment came from their own doctor, picked 74 percent of the time. Ads managed 2 percent and podcast hosts 1 percent; friends and family, at 18 percent, were the only other meaningful influence.
Ketamine businesses do advertise heavily, and patients in St. Charles County will see those ads. But seeing an ad and acting on it are different things. The survey suggests most patients hold off on acting until a physician they trust has weighed in.
Assumption: most patients start by searching online
Searching and seeking care are separate steps. When we asked where respondents would go first if they wanted a newer depression treatment, 12 percent said they would search online. More than four times as many, 56 percent, named primary care, and 23 percent a psychiatrist.
For a primary care practice, that is both a compliment and an obligation. You are the front door for most of these patients, whether or not your practice has thought of itself that way.
Assumption: a patient asking about "alternatives" is against medication
One respondent wrote "depression medicine alternatives" as their search phrase. It is tempting to hear that as a rejection of drugs. It may be. It may also mean frustration with a medication that has not helped, concern about side effects, or curiosity about anything new.
The survey offers some texture without resolving it. Sixty-four percent of respondents valued a drug-free option, yet only 25 percent knew TMS, which is one. Interest in non-drug approaches is high and knowledge of them is low. A clarifying question works better than an assumption: "When you say alternatives, what are you hoping for?"
Assumption: skepticism means the answer is no
Patients who hear "ketamine" may react warily. That is not the same as refusal. In the survey, first reactions to ketamine therapy put 34 percent at cautious but open, 21 percent at skeptical, and 18 percent at hopeful or curious. A mere 9 percent reacted negatively, and the remaining 18 percent had no prior exposure to the idea at all.
Skeptical patients deserve clear information: what the treatment is, what it is approved for, where and how it is given, and its risks. Esketamine is administered at certified sites with monitoring afterward, which differs sharply from at-home ketamine services and from off-label IV ketamine. Many skeptics are reacting to the at-home model they have seen advertised.
What this means for a St. Charles County practice
- Raise the topic yourself. Patients whose depression has not responded to treatment are unlikely to ask about newer options by name. A brief question at follow-up visits can open the door.
- Explain before you name. Describe the treatment in plain terms, then give the name so the patient can look it up correctly. A plain-language Spravato overview can reinforce it afterward.
- Know your local options by payer. Most St. Charles County patients are on the Missouri side of every insurance question, including MO HealthNet, commercial plans, and Medicare. With 85 percent of respondents putting coverage in their top two, so a referral to an in-network clinic matters.
- Account for the drive. Some specialty options may be in St. Charles County and others a bridge crossing away in St. Louis County. Forty-three percent of respondents counted closeness to home in their top two, and esketamine requires a ride home after every session.
- Clarify the ketamine landscape. A sentence distinguishing the approved nasal spray from at-home and IV ketamine can save a patient from a confusing detour.
Scope
These are findings about how people search and choose care, not clinical evidence or practice guidance. Whether any patient is a candidate for esketamine or another treatment is a clinical decision.
When a patient's words sound like the respondent who typed "someone please help me," set the referral aside and assess safety. Make sure every patient also knows the Suicide and Crisis Lifeline: 988, reachable by phone or text whatever the hour. Veterans who call can press 1.
Methodology
Findings are from a survey our publisher paid for and commissioned, fielded on Pollfish's consumer panel and closed out June 23, 2026. Its participants, 443 of them, all 18 to 64 years old, lived in Nebraska, Missouri, Iowa, Ohio, Kansas, Illinois, Oklahoma, Indiana, Wisconsin, and Minnesota, and 319 answered the open search question. We cite ten-state top-line figures, not county data, all checked in the final panel validation.